Frequencies of HER‐2/neu overexpression relating to HLA haplotype in patients with gastric cancer

We have identified that HER‐2/neu‐derived peptides are naturally processed as tumor rejection antigens recognized by tumor‐specific, HLA‐A2‐restricted cytotoxic T lymphocytes in gastric cancer. To evaluate candidates for immunotherapy using HER‐2/neu‐derived, HLA‐A2‐restricted peptides, we examined...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2002-03, Vol.98 (2), p.216-220
Main Authors: Kono, Koji, Takahashi, Akihiro, Amemiya, Hideki, Ichihara, Fumiko, Sugai, Hidemitsu, Iizuka, Hidehiko, Fujii, Hideki, Matsumoto, Yoshiro
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
gastric cancer
gastric carcinoma
Gastroenterology. Liver. Pancreas. Abdomen
Gene Frequency
Haplotypes
HER2 gene
HER‐2/neu
histocompatibility antigen HLA
HLA Antigens - genetics
HLA haplotype
HLA-A2 Antigen - genetics
Humans
Immunohistochemistry
Lymphocytes, Tumor-Infiltrating - immunology
Medical sciences
neu gene
Receptor, ErbB-2 - biosynthesis
Receptor, ErbB-2 - immunology
Stomach Neoplasms - genetics
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
T-Lymphocytes, Cytotoxic - immunology
TILs
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have identified that HER‐2/neu‐derived peptides are naturally processed as tumor rejection antigens recognized by tumor‐specific, HLA‐A2‐restricted cytotoxic T lymphocytes in gastric cancer. To evaluate candidates for immunotherapy using HER‐2/neu‐derived, HLA‐A2‐restricted peptides, we examined the frequency of HLA‐A2 relating to HER‐2/neu overexpression or the infiltrating grade of tumor‐infiltrating lymphocytes (TILs) in Japanese patients with gastric cancer. HER‐2/neu‐overexpressing tumors detected by immunohistochemistry amounted to 19% of primary gastric cancers and HLA‐A2‐positive patients with gastric cancer were 31% of primary gastric‐cancer cases. Finally, gastric‐cancer patients with both HLA‐A2‐positive and HER‐2/neu‐overexpressing tumors amounted to 6.6% of these cases. There was no significant difference in the infiltrating grade of TILs between gastric cancers overexpressing HER‐2/neu and those that did not. The candidate for HER‐2/neu‐based immunotherapy with HLA‐A2‐restricted peptides represent a very limited population of Japanese patients. © 2001 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.10179